Bleomycin (BLM) is clinically used mainly in combination with other chemotherapeutic agents in the treatment of neoplasms such as squamous cell carcinomas, testicular carcinomas, and lymphoma [1] . Its major adverse effect is pulmonary toxicity, including alveolitis and pulmonary fibrosis [2] .
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The pulmonary toxicity induced by BLM has been observed in a variety of animals including mice [3, 4] , rats [5] , hamsters [6] , guinea pigs [7] , rabbits [8] , dogs [9] , monkeys [10] , baboons [11] , and pheasants [12] , but differences in sensitivity to the induced pulmonary toxicity among strains of a given species has not been studied in detail.
In this paper, the sensitivity to the pulmonary fibrosis caused by BLM in various strains of mice is reported, and the relationship between the sensitivity and the levels of reducing agents or of active oxygen-detoxicating enzymes in the lungs is discussed.
MATERIALS AND METHODS
Chemicals and animals. Commercial BLM, including A2, B2, A5, etc., was prepared at Nippon Kayaku Co. Ltd., Tokyo. Superoxide dismutase (SOD, 2,700 U/mg protein), catalase (2,000 U/mg protein), and glutathione (GSH) reductase (160 U/mg protein) were purchased from Sigma Chemical Co., USA. All other chemicals were of reagent grade.
Seven-week-old male DBA/2, BALB/c, C3H/He, C57BL/6, and various F1 mice were obtained from Charles River Japan (Atsugi, Japan). Seven-week-old male ICR mice and congenic mice of C57BL/ 10 were obtained from Shizuoka Laboratory Animal Center (Hamamatsu, Japan). All animals were used in the study 1 week after being delivered.
BLM administration. BLM was administered i. v. in a volume of 50 p1/mouse at a dose of 7.14 mg/kg/day for 7 days. The total dose of 50 mg/kg for each strain was optimal for the evaluation of the pulmonary fibrosis.
Morphological evaluation of the pulmonary toxicity. Animals were sacrificed 5 weeks after the last administration of BLM. The lobes of lung were fixed in 10 formalin solution, embedded in paraffin, processed, and subjected to both hematoxylin-eosin and azan-Mallory staining. The pulmonary toxicity was evaluated as reported previously [4] .
Preparation of lung homogenates. The lungs of 8-week-old mice sacrificed by exsanguination were washed with cold saline to remove blood as much as possible. After removal of tracheobronchial and vascular tissues, the lungs were minced and homogenized in 20 volumes of 0.1 M phosphate buffer containing 5 mM EDTA (pH 7.4) with a Potter-Elvehjem Teflon homogenizer and centrifuged at 12,000 x g for 20 min at 0°C. The supernatant thus obtained was used in the experiments. The protein content was measured by Lowry's method [13] .
Assay of enzymes. SOD activity of the above supernatant was determined according to McCord and Fridovich [14] . The activities of glutathione peroxidase and glutathione reductase were measured by the methods of Little and O'Brien and Horn, respectively [15, 16] . Catalase activity was determined by the method of Cohen et al. [17] .
Biochemical analysis. Reduced GSH was determined according to Grassetti and Murry [18] . Total ascorbic acid (ASA) was determined by colorimetry of the condensation product with 2,4-dinitrophenylhydrazine after oxidation of the reduced form of ascorbic acid by bromine [19] . Total tocopherol (Toc) was determined by the method of Katsui [20] .
RESULTS
Sensitivity to BLM-induced pulmonary fibrosis in various strains of mice As shown in Table 1 , pulmonary fibrosis was induced in all strains examined. However, the degree of the fibrosis varied with the strains. ICR and C3H/He(H2k) were highly sensitive to the fibrosis induction. C57BL/6(H 2b), DBA/2(H-2d), and A/J(H 2a) were moderate responders, and CBA/JN(H-2k) and BALB/c(H 2d) were the lowest responders.
Pulmonary fibrosis in F1 mice
As shown in Table 2 , strong fibrosis was observed in B6C3F 1 and BDF 1 mice, which were obtained by pairing of moderate and/or high responders. On the other hand, weak fibrosis was observed in CBF1 and CDF1, which were obtained by pairing of low and moderate responders.
Pulmonary fibrosis in congenic mice
Among congenic mice, the degree of the fibrosis was most severe in C57BL/ 10(H 2b) mice, moderate in B 10 . D2(H 2d) mice, and slight in B 10. BR(H-2k) and Table 3 ). The results suggest that major histocompatibility complex (H-2) genes are involved in the sensitivity to the fibrosis.
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Relationship between sensitivity to fibrosis and the activities of enzymes which are involved in the detoxication of active oxygen species As shown in Table 4 , activities of SOD, catalase, GSH peroxidase and, GSH reductase in the lungs varied with strains of mice. But no obvious correlation of these enzyme activities with the sensitivity to fibrosis was observed.
Relationship between sensitivity to fibrosis and amounts of reducing agents in the lungs in various strains of mice As shown in Table 5 , the levels of AsA, GSH, and Toc in the lungs were different among the strains of mice examined. The relationships between the sensitivity to fibrosis induction and the amounts of reducing agents are shown in Fig.  1 . The AsA and Toc levels were inversely correlated with the sensitivity to fibrosis except in BALB f c mice and its F1, but there was no correlation between the sensitivity and the GSH level. These results suggest that some reducing agents play an important role in the sensitivity to the induced fibrosis. In the present study, the sensitivity of the animals to BLM-induced pulmonary fibrosis was found to differ among the strains of mice (Tables 1 and 2 ). In order to understand the difference, we have studied the sensitivity in congenic mice which differ from each other only in the H-2 locus and found the involvement of major histocompatibility complex (H-2) genes (Table 3) . This is suggestive for the investigation of pathogenesis of the BLM-induced pulmonary fibrosis, because idiopathic pulmonary fibrosis in humans is reported to be associated with the presence of MLA-DrW2 [21] . But, as shown in Table 1 , the different sensitivity to the fibrosis was not explained only by the H-2 haplotype. For instance, the haplotypes of low 
Relationship
between degree of fibrosis and lung contents of low molecular weight reducing agents.
Vol. 2, No. 1, 1987 responders in congenic mice B 10 . A and B 10 • BR are a and k, respectively, while a and k are also the haplotypes of a high responder C3H/He and a moderate responder A/J, respectively. In addition, the levels of reducing agents in the lungs of congenic mice were inversely correlated with the sensitivity of the fibrosis (Fig.  1) . Therefore, the sensitivity to the fibrosis in various strains of mice is concluded to be influenced by both H-2 and non H-2 genes. The different sensitivity to the BLM-induced pulmonary fibrosis in mice could be partly explained by the contents in the lungs of reducing agents such as AsA and Toc except in the case of BALB/c and its F 1 mice (Fig. 1) . That is, the higher the lung levels of reducing agents, the weaker the fibrosis. This result well coincides with our previous findings : Administration of Toe [22] , AsA or GSH [23] suppressed pulmonary fibrosis in mice, and exposure of mice to 75% 02 prior to BLM administration increased the lung levels of reducing agents resulting in suppression of the pulmonary fibrosis [24] .
BALB/c and its F 1 mice were low responders although the lung levels of reducing agents were low (Table 5) . Thus, factors other than reducing agents must also be involved in their lower sensitivity to the fibrosis. Schrier and Phan [25] reported that BALB/c mice could be modulated to be highly sensitive to the fibrosis by administration of cyclophosphamide, which is cytotoxic for suppressor T cells, and suggested that immune systems play a role in the fibrogenic process. We also reported an immunological involvement in pulmonary fibrosis [26] . Contrary to the case of Schrier and Phan, cyclophosphamide suppressed the fibrosis in highresponder ICR mice. Therefore, variation of the immunological condition in mice is likely to be another factor influencing the induction of pulmonary fibrosis.
